Gapping up
In reaction to strong earnings/guidance: NEO +47.5%, INFN +15.3%, ETFC +5.9%, SBUX +4.5%, MXIM +4.5%, UPI +3.2%, RMD +3.1%, FHN +2.3%, FII +2%, (light volume), HON +1.6%, PLCM +1.4%, MCD +1.2%, GE +1.1%
M&A news: APP +25% (attributed to speculation of Lions Capital bid for $1.30/share) PT +7% (Oi SA disclosed that shareholders approved the sale by Oi of all of the shares of PT Portugal SGPS S.A. to Altice Portugal S.A.), PAHC +3.6% (acquired exclusive North American distribution rights for MJ Biologicals vaccine technologies; focused on the swine industry and additional vaccines for future development), TEF +1.1% (Hutchison Whampoa (HUWHY) confirms exclusive negotiations for potential acquisition of TEF's O2 UK for GBP 9.25 bln )
Other news: NBG +10.1% (ahead of Greek elections on Sunday), VTAE +7.1% (announces the pricing of its follow-on public offering of 3 mln shares of its common stock at $11.90 per share), FRO +6.6% (still checking), SMLP +4.3% (increased Q4 distribution 3.7% to $0.56 from $0.54 per share), VSTM +3.4% (prices 7,250,000 shares of its common stock at $6.50 per share), INVN+3.4% (in symp with MXIM earnings), MDCO +2.8% (receives CHMP positive opinions for three hospital acute care products), SNE +2.7% (files for extension n of the deadline for Sony to file its quarterly securities report for Q3 due to cyber attack), MIK +2.5% (prices 18,800,000 shares of its common stock at a price of $23.52 per share by selling shareholders), EMES +1.8% (declared a cash distribution of $1.41 for the fourth quarter of 2014), BUD +1.6% (favorable commentary on Thursday's Mad Money), CELG +1.4% (receives positive chmp opinion for ABRAXANE for first-line treatment of patients with Non-Small Cell Lung Cancer), CPRX +1% (EVP, Chief Commercial Officer disclosed purchase of 21000 shares, worth total of $62.1K ), .
Analyst comments: VVUS +6.6% (initiated with a Outperform at RBC Capital Mkts), LULU +3.5% (upgraded to Overweight from Neutral at JP Morgan), LNKD +2.3% (upgraded to Strong Buy at Raymond James), CRH +2.3% (upgraded to Overweight at HSBC Securities), PTCT +2.2% (initiated with a Outperform at RBC Capital Mkts), CY +2.2% (upgraded to Neutral from Underweight at JP Morgan), KORS +1.9% (upgraded to Buy at Mizuho), OUBS +1.8% (to Issue additional Tier 1 capital instrument for employee compensation; supplementary capital return of CHF 0.25 per share following completion of squeeze-out), NUE +1.4% (upgraded to Buy from Neutral at Goldman), OREX +1.3% (initiated with a Outperform at RBC Capital Mkts), CRL +1% (upgraded to Outperform from Market Perform at William Blair)
In reaction to strong earnings/guidance: NEO +47.5%, INFN +15.3%, ETFC +5.9%, SBUX +4.5%, MXIM +4.5%, UPI +3.2%, RMD +3.1%, FHN +2.3%, FII +2%, (light volume), HON +1.6%, PLCM +1.4%, MCD +1.2%, GE +1.1%
M&A news: APP +25% (attributed to speculation of Lions Capital bid for $1.30/share) PT +7% (Oi SA disclosed that shareholders approved the sale by Oi of all of the shares of PT Portugal SGPS S.A. to Altice Portugal S.A.), PAHC +3.6% (acquired exclusive North American distribution rights for MJ Biologicals vaccine technologies; focused on the swine industry and additional vaccines for future development), TEF +1.1% (Hutchison Whampoa (HUWHY) confirms exclusive negotiations for potential acquisition of TEF's O2 UK for GBP 9.25 bln )
Other news: NBG +10.1% (ahead of Greek elections on Sunday), VTAE +7.1% (announces the pricing of its follow-on public offering of 3 mln shares of its common stock at $11.90 per share), FRO +6.6% (still checking), SMLP +4.3% (increased Q4 distribution 3.7% to $0.56 from $0.54 per share), VSTM +3.4% (prices 7,250,000 shares of its common stock at $6.50 per share), INVN+3.4% (in symp with MXIM earnings), MDCO +2.8% (receives CHMP positive opinions for three hospital acute care products), SNE +2.7% (files for extension n of the deadline for Sony to file its quarterly securities report for Q3 due to cyber attack), MIK +2.5% (prices 18,800,000 shares of its common stock at a price of $23.52 per share by selling shareholders), EMES +1.8% (declared a cash distribution of $1.41 for the fourth quarter of 2014), BUD +1.6% (favorable commentary on Thursday's Mad Money), CELG +1.4% (receives positive chmp opinion for ABRAXANE for first-line treatment of patients with Non-Small Cell Lung Cancer), CPRX +1% (EVP, Chief Commercial Officer disclosed purchase of 21000 shares, worth total of $62.1K ), .
Analyst comments: VVUS +6.6% (initiated with a Outperform at RBC Capital Mkts), LULU +3.5% (upgraded to Overweight from Neutral at JP Morgan), LNKD +2.3% (upgraded to Strong Buy at Raymond James), CRH +2.3% (upgraded to Overweight at HSBC Securities), PTCT +2.2% (initiated with a Outperform at RBC Capital Mkts), CY +2.2% (upgraded to Neutral from Underweight at JP Morgan), KORS +1.9% (upgraded to Buy at Mizuho), OUBS +1.8% (to Issue additional Tier 1 capital instrument for employee compensation; supplementary capital return of CHF 0.25 per share following completion of squeeze-out), NUE +1.4% (upgraded to Buy from Neutral at Goldman), OREX +1.3% (initiated with a Outperform at RBC Capital Mkts), CRL +1% (upgraded to Outperform from Market Perform at William Blair)